Ugur Ayturk, PhD
About Dr. Ayturk
Dr. Ugur Ayturk joined Hospital for Special Surgery in Fall 2017 as an Assistant Scientist. Prior to coming to HSS, Dr. Ayturk was an Instructor in Orthopaedic Surgery at Boston Children's Hospital and Harvard Medical School. He completed his PhD work at Colorado State University, and trained as a postdoctoral fellow in the Department of Orthopaedic Surgery at Boston Children's Hospital.
Research
Our goal is to develop an improved understanding of osteoblasts, and use this knowledge to enhance their bone forming capabilities. We are specifically interested in how osteoblasts differentiate from mesenchymal precursors, and how their activities and molecular identity are altered under genetic and environmental perturbations. We use a multitude of approaches including transcriptional profiling (bulk and single cell RNA-seq), genetic modification of mouse models and primary cell culture in our investigations.
Profile Video
Credentials
Appointments
Assistant Scientist, Musculoskeletal Integrity Program
Assistant Professor of Physiology and Biophysics in Orthopaedic Surgery, Weill Cornell Medicine
Affiliations
Department of Orthopaedic Surgery, Weill Cornell Medicine
Education
Phd, Colorado State University
Languages
EnglishPublications by Dr. Ayturk
Selected Journal Articles
Huang R, Balu AR, Molitoris KH, White JP, Robling AG, Ayturk UM*, Baht GS*. The role of Meteorin-like in skeletal development and bone fracture healing. J Orthop Res, in press, 2022. (* Corresponding authors)
Xia Y, Sokhi UK, Bell RD, Pannellini T, Turajane K, Niu Y, Frye L, Chao M, Ayturk U, Otero M, Bostrom M, Oliver D, Yang X, Ivashkiv LB. Immune and repair responses in joint tissues and lymph nodes after knee arthroplasty surgery in mice. Journal of Bone and Mineral Research, 36: 1765-1780, 2021.
Vesprey A, Suh ES, Göz Aytürk D, Yang X, Rogers M, Sosa B, Niu Y, Kalajzic I, Ivashkiv LB, Bostrom MPG, Ayturk UM*. Tmem100- and Acta2-lineage cells contribute to implant osseointegration in a mouse model. Journal of Bone and Mineral Research, 36: 1000-1011, 2021 (* Corresponding author).
Diegel CR, Hann S, Ayturk UM, Hu JCW, Lim KE, Droscha CJ, Madaj ZB, Foxa GE, Izaguirre I, Transgenics Core VVA, Paracha N, Pidhaynyy B, Dowd TL, Robling AG, Warman ML, Williams BO. An osteocalcin-deficient mouse strain without endocrine abnormalities. PLoS Genetics, 16: e1008361, 2020.
Ayturk UM*, Scollan JP, Ayturk DG, Suh ES, Vesprey A, Jacobsen CM, Pajevic PD, Warman ML. Single cell RNA sequencing of calvarial and long bone endorcortical cells. Journal of Bone and Mineral Research, 35: 1981-1991, 2020 (* Corresponding author).
Ayturk UM, Sieker JT, Haslauer CM, Proffen BL, Weissenberger MH, Warman ML, Fleming BC, Murray MM. Proteolysis and cartilage development are activated in the synovium after surgical induction of post traumatic osteoarthritis. PLoS One, 15: e0229449, 2020.
Ayturk UM*, Couto JA*, Hann S, Mulliken JB, Williams KL, Huang Y, Fishman SJ, Boyd TK, Kozakewich HPW, Bischoff J, Greene AK, Warman ML. Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma. American Journal of Human Genetics 2016, 98: 789-795 (*Equal contribution by the authors).
Bowen ME, Ayturk UM, Kurek KC, Yang W, Warman ML. SHP2 regulates chondrocyte terminal differentiation, growth plate architecture, and skeletal cell fates. PLOS Genetics 2014, 10(5):e1004364.
Kedlaya R, Veera S, Horan DJ, Moss RE, Ayturk UM, Jacobsen CM, Bowen ME, Pazsty C, Warman ML and Robling AG. Sclerostin inhibition reverses skeletal fragility in an Lrp5 deficient mouse model of OPPG syndrome. Science Translational Medicine 2013, 5:211ra518.
Ayturk UM, Jacobsen CM, Christodoulou DC, Gorham J, Seidman JG, Seidman CE, Robling AG and Warman ML. An RNA-seq Protocol to Identify mRNA Expression Changes in Mouse Diaphyseal Bone: Applications in Mice with Bone Property Altering Lrp5 Mutations. Journal of Bone and Mineral Research 2013, 28: 2081-93.
Industry Relationships
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Research staff at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however, HSS also believes that these collaborations must be disclosed. As part of the disclosure process, this website lists Research staff collaborations with outside companies if the Research staff member received any payment during the prior year or expects to receive any payment in the next year. The disclosures are based on information provided by the Research staff and other sources and are updated regularly. Current ownership interests and leadership positions are also listed. Further information may be available on individual company websites.
As of May 11, 2024, Dr. Ayturk reported no relationships with the healthcare industry.
By disclosing the collaborations of HSS Research staff with industry on this website, HSS and its Research staff make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit payment of royalties on products developed by him/her that are used on patients at HSS. Feel free to ask the Research staff member about their relationship(s).